Technology Assessment Reviews for NICE
We are funded by the NIHR as an independent Technology Assessment Review (TAR) centre to inform the development of guidance by the National Institute for Health and Care Excellence (NICE). Our research helps NICE’s advisory committees to make evidence-based decisions on the use of new innovative treatments and diagnostic tests for the NHS. NICE guidance helps to ensure that NHS patients can access the most clinically and cost-effective treatments.
Examples of our recent work informing NICE guidance include:
- long-term conditions: bimekizumab for plaque psoriasis
- cancers: tucatinib for advanced breast cancer
- rare diseases: avalglucosidase alfa for Pompe disease
- diagnostic tests: transperineal biopsy for suspected prostate cancer
Further information about NICE guidance is available on their website.
The evaluation reports produced by SHTAC are a key component of the evidence informing health service decision making. The reports are available open access from the NIHR Journals Library Health Technology Assessment series, as well as on NICE’s website.
